http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : ( Ch. Bolormaa ) (검색결과 3 건)
- 무료
- 기관 내 무료
- 유료
-
Epidemiology and Genotype Distribution of HCV in Mongolia
( Sosorbaram Ariunaa ),( D. Munkh-orshikh ),( Ch. Bolormaa ),( B. Gansaikhan ),( Oidov Baatarkhuu ) 대한간학회 2016 춘·추계 학술대회 (KASL) Vol.2016 No.1
Aims: Mongolia is a unique country with high endemicity for three blood borne hepatitis viruses, namely HBV, HCV and HDV. The number of patients with acute hepatitis decreased considerably with an estimated annual number of cases 13,000/ year in 1991 to 1700/year in 2013 in Mongolia.Hepatitis B and C virus infection are one of the major causes of liver cirrhosis and HCC in Mongolia. However, viral hepatitis C is still one of the serious public health concerns in Mongolia. To investigate of HCV infection among apparently healthy populations in Mongolia. Methods: The study population was consisted of 1512 subjects from 13 provinces and Ulaanbaatar city which is the capital city of Mongolia, and the age ranged from 0 to 80 years. Results: According to our study results, the prevalence of anti-HCV was 15.6%, and the HCV RNA was detected in 11 %; therefore, we can say that the prevalence of this infection is very high in Mongolia.The prevalence of anti-HCV and HCV RNA had a tendency to increase with age. The prevalence of anti-HCV and HCV RNA in population aged over 61 years was significantly higher than those aged 31 to 40 year. The history of dental care, surgery, and tattooing was significantly more frequent in anti-HCV positive subjects compared with anti-HCV negative subjects. Interestingly, the most of HCV infection is caused by genotype 1. However, Genotype 2 of HCV is very rare, less than 2 percent in Mongolia. The extreme predominance of HCV genotype 1b in the Mongolian population may be explained by the greater ethnic and genetic homogeneity of current Mongolian population. Conclusions: The epidemiological situation of HCV infection in Mongolia is catastrophic. This infection was evenly distributed in all areas and has endemic characteristics for the country. The rate of positive anti-HCV and HCV-RNA was increasing age-dependently. The predominant genotype of HCV in Mongolia is 1b.
-
( O. Baatarkhuu ),( B. Davaakhuu ),( N. Naranzul ),( Ch. Gantuul ),( Ch. Bolormaa ),( P. Delgermaa ),( S. Ariunaa ),( G. Sarangua ),( G. Khishigjargal ),( D. Javzmaa ),( D. Ouyntuya ),( S. Nyamaa ),( 대한간학회 2017 춘·추계 학술대회 (KASL) Vol.2017 No.1
Aims: In Mongolia, previous studies shown HCV prevalence is over 10% and 97-98% of people with HCV infection have infected with genotype 1b. In addition, Mongolia is on first place of HCC mortality rate per 100.000 population and this is eighth times higher than globally average rate. HCV prevalence among primary hepatic carcinoma patients is 35%-45%. Therefore activities on reducing chronic infection prevalence of hepatitis viruses and preventing complications of hepatitis viral infections have been conducted in the country. One of them is availability of Harvoni treatment for HCV patients since December 2015. To evaluate data on the antiviral efficacy and safety of direct acting antiviral (DAA) treatment with respect to sustained virological response (SVR) 12 weeks after completion of treatment. Methods: We retrospectively analyzed patient monitoring records and patient registration forms for HCV patients who received Harvoni treatment at NCCD, MNUMS, provinces and districts hospitals. Quantitative methods were applied in that retrospective study. Six hundred and forty-seven patients diagnosed as HCV and treated by Harvoni(ledipasvir/sofosbuvir) were attended the study. Results: There were totally 647 patients received Harvoni for HCV infection by September 2016. People who received treatment for less than 3 months there 31% and for longer than 3 months were 8%. Among them 91.9% have chronic hepatitis and first stage of liver cirrhosis and 8% have liver cirrhosis and carcinoma. After 1 month of treatment, HCV RNA tests result was negative for 98.8% of all Harvoni patients and for the rest 1.1% resulted in decrease of HCV RNA.After 3 month of trerapy, blood test result showed 100% recovery on transaminase level. 453/465, 10/465 and 2/465 of them were respectively genotype 1b, 2 and 1a. APRI score were pre-treatment 1.3±0.58 and post treatment 0.443±0.148. FIB4 score were pre-treatment 3.8±1.2 and post treatment 1.65±0.59. Occurrences of side effects were mild. 1.2%, 5.8% and 4.6% of them were respectively with CTP C, CTP B and CTP A scores. 88.2% of the participants were chronic hepatitis C and 1.7% of them were pre-treated by interferon. Conclusions: After treatment by Harvoni tablets, excellent SVR12 results were shown among the study participants’ and the favorable side-effect profile were observed for the Mongolian context.
-
( Оidov Baatarkhuu ),( Dashchirev Munkh-orshikh ),( G. Uugantsetseg ),( B. Davaakhuu ),( N. Naranzul ),( S. Ariunaa ),( Ch. Gantuul ),( Ch. Bolormaa ) 대한간학회 2017 춘·추계 학술대회 (KASL) Vol.2017 No.1
Aims: Mongolia is one of the highest prevalent of hepatitis C virus infection of the world. The standard therapy for patients with genotype 1 chronic hepatitis C (CHC) is a combination of peg-interferon alfa -2a and ribavirin for 48 weeks. However the most appropriate duration of treatment remains to be established because of treatment -related side effects and cost. To compare the efficacies of 24-week and 48-week treatments of peg-interferon alfa-2a plus ribavirin in Mongolian patients Methods: A total of 47 patients with genotype 1 CHC was treated between August 2008 and were randomly assigned to treatment and December 2013 and at least one dose of study medication, consisting of 180 mg of peginterferonalfa 2-a once weekly plus daily ribavirin(1000 or 1200mg, depending on body weight). Patients with undetectable HCV RNA at 24 weeks of treatment were allowed to choose either 24 or 48 weeks as the duration of their treatment ; 4 patients chose the 24 week treatment regimen and the 43 patients chose the 48-week regimen. Results: The SYR rate was higher in patients treated for 48 weeks than in those treated for24 weeks(74% vs 48.8%, p=0.0013). In the multivariate analysis, age < 52 years, platelets >148000mm3, and treatment duration for 48 weeks remained significant independent predictors of SVR. Fortheen of the 47 patients who relapsed in the 24-week treatment group received split 24-week therapy, and 3 patients was achieved SVR. The overall SVR rate did not differ significantly between the 24-week treatment group, including those who underwent 24-week split therapy 48.8%, and the 48-week treatment group (48.8% vs 74%). Conclusions: SVR rate was 74% of the patients in Mongolia.The 24-week therapy following failure is a useful treatment strategy for patients with genotype 1b chronic hepatitis C.
연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
